公开(公告)号：US20170174688A1

公开(公告)日：2017-06-22

申请号：US14972482

申请日：2015-12-17

Applicant: AbbVie Inc.

Inventor： Yujia Dai ,  William McClellan ,  Mike Michaelides ,  Ramzi Sweis ,  Noel Wilson ,  Justin Dietrich

IPC: C07D473/34 ,  C12Q1/48 ,  C07D519/00

CPC classification number: C07D473/34 ,  C07D519/00 ,  C12Q1/48 ,  G01N2333/91017 ,  G01N2500/04

Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US09932340B2

公开(公告)日：2018-04-03

申请号：US14972482

申请日：2015-12-17

Applicant: AbbVie Inc.

Inventor： Yujia Dai ,  William McClellan ,  Mike Michaelides ,  Ramzi Sweis ,  Noel Wilson ,  Justin Dietrich

IPC: C07D473/34 ,  C07D519/00 ,  C12Q1/48

CPC classification number: C07D473/34 ,  C07D519/00 ,  C12Q1/48 ,  G01N2333/91017 ,  G01N2500/04

Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).

公开(公告)号：US20170349589A9

公开(公告)日：2017-12-07

申请号：US14972482

申请日：2015-12-17

Applicant: AbbVie Inc.

Inventor： Yujia Dai ,  William McClellan ,  Mike Michaelides ,  Ramzi Sweis ,  Noel Wilson ,  Justin Dietrich

IPC: C07D473/34 ,  C07D519/00 ,  C12Q1/48

CPC classification number: C07D473/34 ,  C07D519/00 ,  C12Q1/48 ,  G01N2333/91017 ,  G01N2500/04

Abstract: The invention provides for compounds of formula (I) wherein R1, R2, R3, R4, R5, and R6 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions mediated and modulated by SUV420H1. Also provided are pharmaceutical compositions comprised of one or more compounds of formula (I).